In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

@article{Hollingshead2004InVA,
  title={In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative},
  author={Melinda G. Hollingshead and Michael Alley and Angelika M. Burger and Suzanne D. Borgel and Christine M Pacula-Cox and H H Fiebig and Edward A. Sausville},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={56},
  pages={115-125}
}
To describe the preclinical basis for further development of 17-dimethyl aminoethylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG, NSC 707545). In vitro proliferation assays, and in vivo model studies in metastatic pancreatic carcinoma and subcutaneous xenograft melanoma and small-cell lung carcinoma models. 17-DMAG emerged from screening studies as a potent geldanamycin analog, with the average concentration inhibiting the growth of the NCI anticancer cell line drug screen by 50% being… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

Hsp90: A New Player in DNA Repair?

Biomolecules • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 36 references

17-DMA-geldanamycin is a novel water soluble orally bioavailable Hsp-90 inhibitor with potent in vitro and in vivo anti-cancer activity (2nd edn)

V Smith, EA Sausville, RF Camalier, HH Fiebig, AM Burger
Proc Am Assoc Cancer Res • 2003
View 5 Excerpts
Highly Influenced

The hollow fiber assay. In: Fiebig HH, Burger AM (eds) Contributions to oncology, vol 54. Relevance of tumor models for anticancer drug development

M Hollingshead, J Plowman, M Alley, J Mayo, E Sausville
1999
View 4 Excerpts
Highly Influenced

Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 1 Excerpt

Preclinical and clinical activity of the molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) in malignant melanoma (2nd edn) (abstract 2966)

U Banerji, P Clarke, +5 authors P Workman
Proc Am Assoc Cancer Res • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…